iCas9-T2A-antiCD19scFv-CD28-CD3z

Item Information
Catalog # Size/Concentration Price
PM-CAR1006 1x10^6 cells $1200.00
2x10^6 cells $1800.00
1x10^7 cells $4800.00
2x10^8 cells $9600.00
1x10^9 cells $0.00
Specification
Product OrderI
Shipping InformationThis product will ship in a box containing dry ice at a temperature of -80°C.  Learn More
Catalog
PM-CAR1006
$0.00
-
+

Contact us to order

Images

Illustration of CAR construct

Cell Culture Products
Figure 1: CAR-T cells expressing the above construct are available from Promab targeting CD19 with inducible

Positive control measured with flow cytometry

Cell Culture Products
Figure 2: Flow cytometry with Fab Ab showing expression of scFv icasp9-CD19 CAR T-cells.

Negative control measured with flow cytometry

Cell Culture Products
Figure 3: T cells that have not been transfected.
Product Overview
Description The inducible caspase-9-CD19 CAR construct consists of FKBP12 gene with mutation F36 to V coding two 12 kDa FK506 binding proteins fused to truncated Caspase9 (135-416; lacking pro-domain), followed by T2A peptide and then CD19scFv-CD28-CD3zeta. Administration of chemical inductor of dimerization (CID) CID (AP1903 or AP20187) results in dimerization of caspase 9 leading to an activated form of the molecule, which then initiates an apoptotic signaling leading to apoptosis of the transduced cell. Introduction of inducible caspase-9 is used for increasing safety of CAR-T cells by decreasing cytotoxicity of CAR-T cells in the presence of dimerization agent.

Please view FAQs here